Mouse Anti-ZIKV E protein Recombinant Antibody (clone 5-1) (CAT#: VS-0623-WK9)

Figure 1 Binding specificity and cross-reactivity of anti-ZIKV E scFvs.

ELISA graph showing ZIKV positive control (anti-ZIKV ENV antibody), DENV2 positive control (Anti-Dengue Virus Type II Antibody), negative control (Mouse anti-EBOVscFv4-2) and 6 scFv antibodies (5-1, 7-2, 38-1, 45-3, 51-2, and 63-1) against ZIKV E and DENV2 E proteins.

Figure 2 ZIKV-binding affinity of purified scFvs, 5-1, 7-2, 38-1, 45-3, 51-2 and 63-1.

Dilutions of the purified antibodies were added to microtiter wells coated with ZIKV (200 ng/well). Bound antibodies were detected by HRP-conjugated rabbit anti-strep tag mouse IgG antibody.

Figure 3 Plaque reduction (PRNT) assay for ZIKVPRVABC59 neutralization by anti-ZIKV scFvs.

The "virus control" represents the result obtained by infection of virus only without addition of antibody. ZIKV was tested against varying concentrations (1, 10, 20, 50 and 100 μg/ml) of each scFv antibody. A murine scFv4-2 is an irrelevant antibody (EBOV-specific) used as negative control.

Figure 4 Neutralization dose-response curve- the PRNT data for each antibody.

The PRNT50 values were measured to predict the therapeutic potency of scFvs by evaluating cytopathic effects in infected Vero cells.